Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Author:
Affiliation:
1. Barbara Davis Center for Diabetes, Department of Medicine and Pediatrics, University of Colorado Denver, Aurora, Colorado, USA.
Publisher
Mary Ann Liebert Inc
Link
https://www.liebertpub.com/doi/pdf/10.1089/dia.2023.0490
Reference14 articles.
1. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
2. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes;Diabetes Therapy;2024-09-14
2. Use of continuous glucose monitoring when initiating glucagon‐like peptide‐1 receptor agonist therapy in insulin‐treated diabetes;Diabetes, Obesity and Metabolism;2024-08-28
3. Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care;Pragmatic and Observational Research;2024-08
4. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes;Diabetes Technology & Therapeutics;2024-06-01
5. Challenges of GLP Analog Use for People with Type 1 Diabetes: Issues with Prior Approvals and Tips for Safer Use;Diabetes Technology & Therapeutics;2024-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3